{"id":60381,"date":"2026-06-04T23:08:02","date_gmt":"2026-06-04T14:08:02","guid":{"rendered":"https:\/\/japanir.jp\/en\/company\/company-6090\/"},"modified":"2026-08-23T12:14:05","modified_gmt":"2026-08-23T03:14:05","slug":"company-6090","status":"publish","type":"company","link":"https:\/\/japanir.jp\/en\/company\/company-6090\/","title":{"rendered":"HUMAN METABOLOME TECHNOLOGIES I"},"content":{"rendered":"","protected":false},"featured_media":0,"template":"","meta":{"Ticker":"6090","DATE":"2026-01-09","longName":"Human Metabolome Technologies, Inc.","company_name_ja":"","fullTimeEmployees":62,"address":"","phone":"","website":"https:\/\/www.humanmetabolome.com","industry":"Diagnostics & Research","sector":"Healthcare","regularMarketPrice":687,"financialCurrency":"","marketCap":3866,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":43.670000000000002,"epsForward":0,"bookValue":0,"totalRevenue":1455004000,"OperatingIncome":249521000,"operatingMargins":17.149999999999999,"NetIncome":256420000,"profitMargins":17.620000000000001,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":13.44,"recommendationMean":0,"recommendationKey":"none","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"{\"success\": true, \"fetched_at\": \"2026-08-01T03:47:43.466506\", \"ticker\": \"6090\", \"ticker_full\": \"6090.T\", \"company_name\": \"HUMAN METABOLOME TECHNOLOGIES I\", \"analyst_recommendations\": {\"has_data\": true, \"recommendation_key\": \"none\", \"recommendation_mean\": null, \"total_analysts\": null, \"strong_buy\": null, \"buy\": null, \"hold\": null, \"sell\": null, \"strong_sell\": null}, \"target_prices\": {\"has_data\": true, \"current\": 599.0, \"high\": null, \"low\": null, \"mean\": null, \"median\": null}, \"earnings_dates\": {\"has_data\": false}, \"shareholders\": {\"has_data\": true, \"insider_pct\": 20.44, \"institution_pct\": 11.71, \"major_holders\": [{\"label\": \"\", \"value\": 20.44}, {\"label\": \"\", \"value\": 11.71}, {\"label\": \"\", \"value\": 14.72}, {\"label\": \"\", \"value\": 4.0}], \"institutional_holders\": [], \"mutualfund_holders\": []}}","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma. The company offers solutions for cancer metabolism, metabolic flux analysis, infectious diseases, basic science, preclinical and clinical, food and nutrition, and microbiome applications. Human Metabolome Technologies, Inc. has a collaboration with the Institute for Advanced Biosciences and Keio University for the development of metabolome analysis technology. The company was incorporated in 2003 and is based in Tsuruoka, Japan.","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":18,"get_dividend_history_year2":15,"get_dividend_history_year3":15,"get_dividend_history_year4":10,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"financial_data":"","detailed_financial_data":"{\"success\": true, \"fetched_at\": \"2026-08-23T01:53:22.362413\", \"ticker\": \"6090\", \"ticker_full\": \"6090.T\", \"company_name\": \"HUMAN METABOLOME TECHNOLOGIES I\", \"company_info\": {\"name_en\": \"HUMAN METABOLOME TECHNOLOGIES I\", \"long_name\": \"Human Metabolome Technologies, Inc.\", \"sector\": \"Healthcare\", \"industry\": \"Diagnostics & Research\", \"website\": \"https:\/\/www.humanmetabolome.com\", \"employees\": null, \"country\": \"Japan\", \"city\": \"Tsuruoka\", \"address\": \"246-2 Mizukami Kakuganji\", \"description\": \"Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma. The company offers solutions for cancer metabolism, metabolic flux analysis, infectious diseases, basic science, preclinical and clinical, food and nutrition, and microbiome applications. Human Metabolome Technologies, Inc. has a collaboration with the Institute for Advanced Biosciences and Keio University for the development of metabolome analysis technology. The company was incorporated in 2003 and is based in Tsuruoka, Japan.\"}, \"price_trend\": {\"ma_5\": {\"ma_value\": 600.0, \"deviation\": 2.0, \"trend\": \"up\"}, \"ma_25\": {\"ma_value\": 593.68, \"deviation\": 3.09, \"trend\": \"up\"}, \"ma_75\": {\"ma_value\": 610.66, \"deviation\": 0.22, \"trend\": \"up\"}, \"ma_200\": {\"ma_value\": 647.03, \"deviation\": -5.41, \"trend\": \"down\"}}, \"financials\": {\"years\": [{\"year\": 2025, \"revenue\": 1455004000.0, \"revenue_fmt\": \"\u00a515\u5104\", \"gross_profit\": 921713000.0, \"gross_profit_fmt\": \"\u00a59\u5104\", \"operating_income\": 249521000.0, \"operating_income_fmt\": \"\u00a52\u5104\", \"ebit\": 272246000.0, \"ebit_fmt\": \"\u00a53\u5104\", \"net_income\": 256420000.0, \"net_income_fmt\": \"\u00a53\u5104\", \"eps\": 43.67, \"operating_margin\": 17.15, \"total_assets\": 2374607000.0, \"total_assets_fmt\": \"\u00a524\u5104\", \"total_equity\": 1908596000.0, \"total_equity_fmt\": \"\u00a519\u5104\", \"total_debt\": 110468000.0, \"total_debt_fmt\": \"\u00a51\u5104\", \"total_cash\": 1562417000.0, \"total_cash_fmt\": \"\u00a516\u5104\", \"equity_ratio\": 80.38, \"de_ratio\": 0.06, \"current_ratio\": 4.14, \"operating_cf\": 373531000.0, \"operating_cf_fmt\": \"\u00a54\u5104\", \"investing_cf\": -197272000.0, \"investing_cf_fmt\": \"-\u00a52\u5104\", \"financing_cf\": -369451000.0, \"financing_cf_fmt\": \"-\u00a54\u5104\", \"free_cf\": 224791000.0, \"free_cf_fmt\": \"\u00a52\u5104\", \"net_margin\": 17.62, \"roe\": 13.44, \"roa\": 10.8}, {\"year\": 2024, \"revenue\": 1345671000.0, \"revenue_fmt\": \"\u00a513\u5104\", \"gross_profit\": 869331000.0, \"gross_profit_fmt\": \"\u00a59\u5104\", \"operating_income\": 220168000.0, \"operating_income_fmt\": \"\u00a52\u5104\", \"ebit\": 263998000.0, \"ebit_fmt\": \"\u00a53\u5104\", \"net_income\": 243248000.0, \"net_income_fmt\": \"\u00a52\u5104\", \"eps\": 41.14, \"operating_margin\": 16.36, \"total_assets\": 2603401000.0, \"total_assets_fmt\": \"\u00a526\u5104\", \"total_equity\": 1946711000.0, \"total_equity_fmt\": \"\u00a519\u5104\", \"total_debt\": 226303000.0, \"total_debt_fmt\": \"\u00a52\u5104\", \"total_cash\": 1788506000.0, \"total_cash_fmt\": \"\u00a518\u5104\", \"equity_ratio\": 74.78, \"de_ratio\": 0.12, \"current_ratio\": 3.31, \"operating_cf\": 236795000.0, \"operating_cf_fmt\": \"\u00a52\u5104\", \"investing_cf\": -32441000.0, \"investing_cf_fmt\": \"-\u00a532.4M\", \"financing_cf\": -73153000.0, \"financing_cf_fmt\": \"-\u00a573.2M\", \"free_cf\": 202696000.0, \"free_cf_fmt\": \"\u00a52\u5104\", \"net_margin\": 18.08, \"roe\": 12.5, \"roa\": 9.34}, {\"year\": 2023, \"revenue\": 1299225000.0, \"revenue_fmt\": \"\u00a513\u5104\", \"gross_profit\": 859752000.0, \"gross_profit_fmt\": \"\u00a59\u5104\", \"operating_income\": 210982000.0, \"operating_income_fmt\": \"\u00a52\u5104\", \"ebit\": 239267000.0, \"ebit_fmt\": \"\u00a52\u5104\", \"net_income\": 285758000.0, \"net_income_fmt\": \"\u00a53\u5104\", \"eps\": 48.39, \"operating_margin\": 16.24, \"total_assets\": 2291058000.0, \"total_assets_fmt\": \"\u00a523\u5104\", \"total_equity\": 1772328000.0, \"total_equity_fmt\": \"\u00a518\u5104\", \"total_debt\": 226521000.0, \"total_debt_fmt\": \"\u00a52\u5104\", \"total_cash\": 1656789000.0, \"total_cash_fmt\": \"\u00a517\u5104\", \"equity_ratio\": 77.36, \"de_ratio\": 0.13, \"current_ratio\": 3.75, \"operating_cf\": 284962000.0, \"operating_cf_fmt\": \"\u00a53\u5104\", \"investing_cf\": -116755000.0, \"investing_cf_fmt\": \"-\u00a51\u5104\", \"financing_cf\": -13754000.0, \"financing_cf_fmt\": \"-\u00a513.8M\", \"free_cf\": 168107000.0, \"free_cf_fmt\": \"\u00a52\u5104\", \"net_margin\": 21.99, \"roe\": 16.12, \"roa\": 12.47}, {\"year\": 2022, \"revenue\": 1223281000.0, \"revenue_fmt\": \"\u00a512\u5104\", \"gross_profit\": 840004000.0, \"gross_profit_fmt\": \"\u00a58\u5104\", \"operating_income\": 191150000.0, \"operating_income_fmt\": \"\u00a52\u5104\", \"ebit\": 264125000.0, \"ebit_fmt\": \"\u00a53\u5104\", \"net_income\": 267785000.0, \"net_income_fmt\": \"\u00a53\u5104\", \"eps\": 45.39, \"operating_margin\": 15.63, \"total_assets\": 2068728000.0, \"total_assets_fmt\": \"\u00a521\u5104\", \"total_equity\": 1486577000.0, \"total_equity_fmt\": \"\u00a515\u5104\", \"total_debt\": 233195000.0, \"total_debt_fmt\": \"\u00a52\u5104\", \"total_cash\": 1504744000.0, \"total_cash_fmt\": \"\u00a515\u5104\", \"equity_ratio\": 71.86, \"de_ratio\": 0.16, \"current_ratio\": 3.19, \"operating_cf\": 324033000.0, \"operating_cf_fmt\": \"\u00a53\u5104\", \"investing_cf\": -152314000.0, \"investing_cf_fmt\": \"-\u00a52\u5104\", \"financing_cf\": 80491000.0, \"financing_cf_fmt\": \"\u00a580.5M\", \"free_cf\": 177919000.0, \"free_cf_fmt\": \"\u00a52\u5104\", \"net_margin\": 21.89, \"roe\": 18.01, \"roa\": 12.94}], \"has_data\": true}, \"dividends\": {\"history\": [{\"year\": 2023, \"amount\": 10.0}, {\"year\": 2024, \"amount\": 15.0}, {\"year\": 2025, \"amount\": 15.0}, {\"year\": 2026, \"amount\": 18.0}], \"latest\": 18.0, \"has_data\": true}}","ma_5_value":0,"ma_5_deviation":0,"ma_5_trend":"","ma_25_value":0,"ma_25_deviation":0,"ma_25_trend":"","ma_75_value":0,"ma_75_deviation":0,"ma_75_trend":"","ma_200_value":0,"ma_200_deviation":0,"ma_200_trend":"","previousClose":0,"open":0,"dayHigh":0,"dayLow":0,"volume":0,"averageVolume":0,"revenueGrowth":0},"sector":[],"class_list":["post-60381","company","type-company","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>HUMAN METABOLOME TECHNOLOGIES I - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-6090\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-6090\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-6090\/\",\"name\":\"HUMAN METABOLOME TECHNOLOGIES I - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-06-04T14:08:02+00:00\",\"dateModified\":\"2026-08-23T03:14:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-6090\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-6090\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-6090\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HUMAN METABOLOME TECHNOLOGIES I\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HUMAN METABOLOME TECHNOLOGIES I - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-6090\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-6090\/","url":"https:\/\/japanir.jp\/en\/company\/company-6090\/","name":"HUMAN METABOLOME TECHNOLOGIES I - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-06-04T14:08:02+00:00","dateModified":"2026-08-23T03:14:05+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-6090\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-6090\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-6090\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"HUMAN METABOLOME TECHNOLOGIES I"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company\/60381","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/company"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=60381"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=60381"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}